Synovial Sarcoma - Pipeline Insight, 2024

Synovial Sarcoma - Pipeline Insight, 2024

DelveInsight’s, “Synovial Sarcoma - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Synovial Sarcoma: Understanding

Synovial Sarcoma: Overview

Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. SS was originally named for its frequent occurrence in the soft tissue around large joints, particularly the knee, and was believed to be of synovial cell origin. It has now been documented in most areas of the body including viscera. Its occurrence within a joint is very rare, and as SS neither arise from nor differentiate toward synovium, the name is a historical error. Synovial sarcoma differs from other STS by the relatively young age at diagnosis and clinical presentation. Synovial sarcomas have unique genomic characteristics and are driven by a pathognomonic t(X; 18) chromosomal translocation and subsequent formation of the SS18: SSX fusion oncogenes.

Similar to other STS, diagnosis can be obtained from a combination of history, physical examination, magnetic resonance imaging, biopsy and subsequent pathology, immunohistochemistry and molecular analysis. Increasing size, age and tumor grade have been demonstrated to be negative predictive factors for both local disease recurrence and metastasis. Wide surgical excision remains the standard of care for definitive treatment with adjuvant radiation utilized for larger and deeper lesions. There remains controversy surrounding the role of chemotherapy in the treatment of SS and there appears to be survival benefit in certain populations. As the understanding of the molecular and immunologic characteristics of SS evolve, several potential systematic therapies have been proposed.

Treatment for synovial sarcoma depends on whether it has spread. Given that synovial sarcoma can grow for a while before it is found, there is a greater chance that it will spread to other parts of the body. Surgery is the first choice of treatment for synovial sarcomas. When all of the tumor is removed and there is no sign of cancer anywhere else in the body, there is a better chance of survival. Success of the surgery depends on the size of the tumor and its location in the body. Sometimes radiation therapy is used before or after surgery to kill cancer cells. Chemotherapy may be used when synovial sarcoma cannot be completely removed by surgery or when it has spread. Researchers are working to develop new treatments for synovial sarcomas. Some are in clinical trials.

""Synovial Sarcoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Synovial Sarcoma pipeline landscape is provided which includes the disease overview and Synovial Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Synovial Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Synovial Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Synovial Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Synovial Sarcoma.

Synovial Sarcoma Emerging Drugs Chapters

This segment of the Synovial Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Synovial Sarcoma Emerging Drugs

• AL3818: Advenchen Laboratories

Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1–4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.

• Tazemetostat: Ipsen

Tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process. Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of synovial sarcoma.

• OTSA101: OncoTherapy Science

OTSA101 is an anti-FZD10 antibody and has been developed as novel cancer therapy for synovial sarcoma. FZD10, which was identified through genome-wide analysis by the group of Professor Yusuke Nakamura (former Director of Human genome center, Institute of Medical Science,The University of Tokyo ) is frequently and highly up regulated in synovial sarcoma but being hardly detectable in normal organs. OTSA101 specifically binds to FZD10 in cancer cells. In addition, radioactive isotope-conjugated OTSA101 showed strong anti-cancer activity by tumor-specific irradiation in mouse xenograft model. Currently, the drug is in the Phase I stage of its development for the treatment of synovial sarcoma.

Further product details are provided in the report……..

Synovial Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Synovial Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Synovial Sarcoma
• There are approx. 15+ key companies which are developing the therapies for Synovial Sarcoma. The companies which have their Synovial Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories.
• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Synovial Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Synovial Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Synovial Sarcoma drugs.

Synovial Sarcoma Report Insights

• Synovial Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Synovial Sarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Synovial Sarcoma drugs?
• How many Synovial Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Synovial Sarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Synovial Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Synovial Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Advenchen Laboratories
• Ipsen
• OncoTherapy Science
• C4 Therapeutics
• Takara Bio
• BioAtla, Inc.
• Immatics Biotechnologies GmbH
• Sapience Therapeutics
• PharmaMar

Key Products

• AL3818
• Tazemetostat
• OTSA101
• CFT 8634
• TBI-1301
• BA-3011
• IMA402
• ST316
• Lurbinectedin